2-(2-{[7-(3-chloropropoxy)-6-methoxyquinazolin-4-yl]amino}-1,3-thiazol-5-yl)-N-(3-fluorophenyl)acetamide | 723278-29-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 2-(2-{[7-(3-chloropropoxy)-6-methoxyquinazolin-4-yl]amino}-1,3-thiazol-5-yl)-N-(3-fluorophenyl)acetamide
• 英文别名: N-(3-fluorophenyl)-2-(2-(7-(3-chloropropoxy)-6-methoxyquinazoline-4-yl-amino) 1,3-thiazole-5-yl)acetamide；N-(3-fluorophenyl)-2-(2-(7-(3-chloropropoxy)-6-methoxyquinazoline-4-yl-amino)-1,3-thiazole-5-yl)acetamide；N-(3-fluorophenyl)-2-(2-(7-(3-chloropropoxy)-6-methoxyquinazolin-4-yl-amino)-1,3-thiazol-5-yl)acetamide；2-[2-[[7-(3-chloropropoxy)-6-methoxyquinazolin-4-yl]amino]-1,3-thiazol-5-yl]-N-(3-fluorophenyl)acetamide
• CAS: 723278-29-3
• 化学式: C₂₃H₂₁ClFN₅O₃S
• 分子量: 501.969
• InChiKey: YPHXNFSBXWNFFU-UHFFFAOYSA-N

物化性质

• 密度：
  1.437±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  34
• 可旋转键数：
  10
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  127
• 氢给体数：
  2
• 氢受体数：
  9

反应信息

• 作为反应物：
  描述：

  2-(2-{[7-(3-chloropropoxy)-6-methoxyquinazolin-4-yl]amino}-1,3-thiazol-5-yl)-N-(3-fluorophenyl)acetamide 在 四氮唑 、 盐酸 、 双氧水 、 potassium iodide 作用下， 以 1,4-二氧六环 、 N-甲基吡咯烷酮 、 N,N-二甲基乙酰胺 为溶剂， 反应 22.0h， 生成 {1-[3-({4-[(5-{2-[(3-fluorophenyl)amino]-2-oxoethyl}-1,3-thiazol-2-yl)amino]-6-methoxyquinazolin-7-yl}oxy)propyl]piperidin-4-yl}methyl dihydrogen phosphate
  参考文献：
  名称：

  Discovery of Novel and Potent Thiazoloquinazolines as Selective Aurora A and B Kinase Inhibitors

  摘要：

  The synthesis of a novel series of quinazolines substituted at C4 by five-membered ring aminoheterocycles is reported. Their in vitro structure-activity relationships versus Aurora A and B serine-threonine kinases is discussed. Our results demonstrate that quinazolines with a substituted aminothiazole at C4 possess potent Aurora A and B inhibitory activity and excellent selectivity against a panel of various serine-threonine and tyrosine kinases, as exemplified by compound 46. We found also that the position and nature of the substituent on the thiazole play key roles in cellular potency. Compounds with an acetanilide substituent at C5' have the greatest cellular activity. The importance of the C5' position for substitution has been rationalized by ab initio molecular orbital calculations. Results show that the planar conformation with the sulfur of the thiazole next to the quinazoline N-3 is strongly favored over the other possible planar conformation. Compound 46 is a potent suppressor of the expression of phospho-histone H3 in tumor cells in vitro as well as in vivo, where 46, administered as its phosphate prodrug 54, suppresses the expression of phospho-histone H3 in subcutaneously implanted tumors in nude mice.

  DOI：

  10.1021/jm050786h
• 作为产物：
  描述：

  [2-(tritylamino)-1,3-thiazol-5-yl]acetic acid 在 溶剂黄146 、 N,N-二异丙基乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 、 三氟乙酸 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 22.0h， 生成 2-(2-{[7-(3-chloropropoxy)-6-methoxyquinazolin-4-yl]amino}-1,3-thiazol-5-yl)-N-(3-fluorophenyl)acetamide
  参考文献：
  名称：

  Discovery of Novel and Potent Thiazoloquinazolines as Selective Aurora A and B Kinase Inhibitors

  摘要：

  The synthesis of a novel series of quinazolines substituted at C4 by five-membered ring aminoheterocycles is reported. Their in vitro structure-activity relationships versus Aurora A and B serine-threonine kinases is discussed. Our results demonstrate that quinazolines with a substituted aminothiazole at C4 possess potent Aurora A and B inhibitory activity and excellent selectivity against a panel of various serine-threonine and tyrosine kinases, as exemplified by compound 46. We found also that the position and nature of the substituent on the thiazole play key roles in cellular potency. Compounds with an acetanilide substituent at C5' have the greatest cellular activity. The importance of the C5' position for substitution has been rationalized by ab initio molecular orbital calculations. Results show that the planar conformation with the sulfur of the thiazole next to the quinazoline N-3 is strongly favored over the other possible planar conformation. Compound 46 is a potent suppressor of the expression of phospho-histone H3 in tumor cells in vitro as well as in vivo, where 46, administered as its phosphate prodrug 54, suppresses the expression of phospho-histone H3 in subcutaneously implanted tumors in nude mice.

  DOI：

  10.1021/jm050786h

文献信息

• [EN] QUINAZOLINE COMPOUNDS<br/>[FR] COMPOSES DE QUINAZOLINE
  申请人：ASTRAZENECA AB

  公开号：WO2004058752A1

  公开（公告）日：2004-07-15

  Quinazoline derivatives of formula (I) wherein A is 5-membered heteroaryl containing a sulphur atom and optionally containing one or more nitrogen atoms; compositions containing them, processes for their preparation and their use in therapy.

  式(I)中的喹唑啉衍生物，其中A是含有硫原子并且可选地含有一个或多个氮原子的5-成员杂芳基；含有它们的组合物，其制备方法以及它们在治疗中的用途。
• Substituted quinazoline derivatives and their use as inhibitors
  申请人：AstraZeneca AB

  公开号：US20030187002A1

  公开（公告）日：2003-10-02

  The use of a compound of formula (I) 1 or a salt, ester or amide thereof; where X is O, or S, S(O) or S(O) 2 , or NR 6 where R 6 is hydrogen or C 1-6 alkyl,; R 5 is an optionally substituted 5-membered heteroaromatic ring, R 1 , R 2 , R 3 , R 4 are independently selected from various specified moieties, in the preparation of a medicament for use in the inhibition of aurora 2 kinase. Certain compounds are novel and these, together with pharmaceutical compositions containing them are also described and claimed.

  使用式(I)的化合物或其盐、酯或酰胺； 其中X为O、S、S(O)或S(O)2，或NR6，其中R6为氢或C1-6烷基； R5为可选择取代的5-成员杂芳环， R1、R2、R3、R4分别选自各种指定的基团，在制备用于抑制aurora 2激酶的药物中使用。 某些化合物是新颖的，这些化合物以及含有它们的药物组合物也有描述和声明。
• Quinazoline compounds
  申请人：Mortlock Austen Andrew

  公开号：US20060058523A1

  公开（公告）日：2006-03-16

  Quinazoline derivatives of formula (I) wherein A is 5-membered heteroaryl containing a sulphur atom and optionally containing one or more nitrogen atoms; compositions containing them, processes for their preparation and their use in therapy.

  公式（I）中的喹嗪啉衍生物，其中A是含有硫原子并可选地含有一个或多个氮原子的五元杂环芳基；包含它们的组合物，制备它们的过程以及它们在治疗中的使用。
• SUBSTITUTED QUINAZOLINE DERIVATIVES AND THEIR USE AS INHIBITORS
  申请人：AstraZeneca AB

  公开号：EP1299381A1

  公开（公告）日：2003-04-09
• QUINAZOLINE COMPOUNDS
  申请人：AstraZeneca AB

  公开号：EP1575946A1

  公开（公告）日：2005-09-21